ACC: Semaglutide beneficial in obesity-related heart failure, type 2 diabetes
Apr 09, 2024
Larger reductions were seen in heart failure-related symptoms and physical limitations for patients with HFpEF and type 2 diabetes.
Long-term care pharmacies forced to borrow to buy resident drugs, close as intermediaries tighten grip...
By
Kimberly Marselas
Apr 08, 2024
Long-term care resident access to prescription drugs is being squeezed as several market and regulatory factors have combined to increase the power that pharmacy benefit managers have over the specialized...
Lixisenatide reduces motor disability progression in Parkinson’s disease
Apr 04, 2024
Lixisenatide results in less progression of motor disability than placebo at 12 months for individuals with early Parkinson’s disease.
Minocycline does not decrease geographic atrophy enlargement in AMD
Mar 25, 2024
The GA enlargement rate in the study eyes did not differ significantly in the run-in and treatment phases in age-related macular degeneration.
Mental health treatment linked to better outcomes in CAD, heart failure
Mar 22, 2024
Patients receiving mental health treatment were less likely to be rehospitalized, have an emergency department visit or die from any cause.
Medicare to cover Wegovy when patients also have heart disease
Mar 22, 2024
Medicare will now cover the popular weight-loss drug Wegovy if patients using it also have heart disease, US officials announced Thursday.
Four in 10 US adults say they know someone who died from drug overdose
Feb 28, 2024
One-third of those say their lives were disrupted by the overdose death.
Single dose of zilebesiran linked to reduction in systolic BP
Feb 20, 2024
A significant reduction was seen in systolic blood pressure with zilebesiran 150, 300 or 600 mg once in six months and 300 mg once every three months.
Expanded use of Xolair to treat food allergies approved by the FDA
Feb 17, 2024
Xolair is not meant to substitute for emergency anaphylaxis medications such as the EpiPen.
Dapagliflozin cuts cardiovascular events in patients with heart failure, T2D
Dec 27, 2023
Dapagliflozin, however, does not reduce the urinary albumin-to-creatinine ratio in those patients.